Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment

Goel A, Chen Q, Chhatwal J, Aggarwal R. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol. 2018;33(12):2029-2036.

Publication Type:

Journal Article

Authors:

Goel, A; Chen, Q; Chhatwal, J.; Aggarwal, R

Source:

J Gastroenterol Hepatol, Volume 33, Issue 12, p.2029-2036 (2018)

Cited On:

Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens

Export Citation:

RIS Format

Top